Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MacroGenics, Inc.
MacroGenics to Participate in Upcoming Investor Conferences
November 06, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Leadership Transition
October 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 29, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 08, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
March 01, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
February 02, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
September 05, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
April 24, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
March 08, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
March 07, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
March 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
February 13, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
February 06, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
January 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
